With the release by Acadia of the positive top-line phase 3 drug trial test results for Trofinetide on 2021-12-07, NEU MC rose strongly and maintained a high close at the end of month.
MC (not SP) is always a better comparative parameter to assess NEU against its peers. LTHs who maintained their share of issued capital during CRs should be in the black.
Market Capitalisation is a Better Valuation Metric Than Share Price, page-5
-
- There are more pages in this discussion • 96 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.70 |
Change
-0.370(2.63%) |
Mkt cap ! $1.746B | |||
| Open | High | Low | Value | Volume |
| $13.73 | $13.88 | $13.40 | $3.470M | 253.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 351 | $13.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.72 | 129 | 2 |
View Market Depth
| Last trade - 11.36am 04/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |